These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

477 related items for PubMed ID: 15855208

  • 1. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D.
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [Abstract] [Full Text] [Related]

  • 2. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
    Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D.
    Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
    [Abstract] [Full Text] [Related]

  • 3. Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.
    de Francisco AL.
    Expert Opin Pharmacother; 2005 Mar; 6(3):441-52. PubMed ID: 15794735
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA.
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU.
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [Abstract] [Full Text] [Related]

  • 7. Cinacalcet hydrochloride (Sensipar) in hemodialysis patients on active vitamin D derivatives with controlled PTH and elevated calcium x phosphate.
    Chertow GM, Blumenthal S, Turner S, Roppolo M, Stern L, Chi EM, Reed J, CONTROL Investigators.
    Clin J Am Soc Nephrol; 2006 Mar; 1(2):305-12. PubMed ID: 17699221
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD, Alvarez-Ude F, Gil MT, Moledous A, Malek T, Nuñez C, Devesa R, Carretón MA, Soriano A.
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [Abstract] [Full Text] [Related]

  • 10. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats.
    Noonan W, Koch K, Nakane M, Ma J, Dixon D, Bolin A, Reinhart G.
    Nephrol Dial Transplant; 2008 Dec; 23(12):3824-30. PubMed ID: 18644798
    [Abstract] [Full Text] [Related]

  • 11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 12. Impact of vitamin D dose on biochemical parameters in patients with secondary hyperparathyroidism receiving cinacalcet.
    Wilkie M, Pontoriero G, Macário F, Yaqoob M, Bouman K, Braun J, von Albertini B, Brink H, Maduell F, Graf H, Frazão JM, Bos WJ, Torregrosa V, Saha H, Reichel H, Zani VJ, Carter D, Messa P.
    Nephron Clin Pract; 2009 Nov; 112(1):c41-50. PubMed ID: 19365139
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study.
    Lindberg JS, Culleton B, Wong G, Borah MF, Clark RV, Shapiro WB, Roger SD, Husserl FE, Klassen PS, Guo MD, Albizem MB, Coburn JW.
    J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407
    [Abstract] [Full Text] [Related]

  • 15. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl.
    Sprague SM, Evenepoel P, Curzi MP, González MT, Husserl FE, Kopyt N, Sterling LR, Mix C, Wong G.
    Clin J Am Soc Nephrol; 2009 Sep; 4(9):1465-76. PubMed ID: 19696213
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis.
    Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG.
    N Engl J Med; 2004 Apr 08; 350(15):1516-25. PubMed ID: 15071126
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.